Anlotinib or Penpulimab in Combination With RAI for DTC

Thyroid Cancer Clinical Trial

Official title:

The Efficacy and Safety of Anlotinib Hydrochloride or Penpulimab In Combination With RAI in Patients With Local Advanced or Metastatic Differentiated Thyroid Cancer: A Randomized, Open-label, Exploratory Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04952493
• Other study ID #: ALTER-T002
• Status: Recruiting
• Phase: Phase 2
• Start date: September 15, 2021
• Est. completion date: July 20, 2024

Study information

• Verified date: August 2021
• Source: Peking Union Medical College Hospital
• Contact: Yansong Lin, MD
• Phone: +86-10-69155610
• Email: linys[@]pumch.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of anlotinib in combination with I-131 in locally advanced/metastatic differentiated thyroid cancer. Anlotinib may stop the growth of tumor cells and improve iodine uptake.

Description:

Primary Outcome Measures:

objective response rate (ORR)

Secondary Outcome Measures：

1. Biochemical Response Rate (BRR) Biochemical response rate is defined as the percentage of subjects whose Tg was consecutive decreases more than 25% compared to baseline twice

2. Disease Control Rate (DCR)

3. Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

4. Nuclear medicine functional imaging changes of target lesions The dynamic changes of I uptake and 18F-FDG PET/CT imaging

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 42
• Est. completion date: July 20, 2024
• Est. primary completion date: July 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• local advanced or metastatic differentiated thyroid cancer (DTC)

• scheduled to receive RAI treatment.

• absence of good remission of RAI or may not get satisfactory remission from RAI treatment

• At least one measurable lesion, with diameter = 10mm measured by spiral MRI/CT scan per RECIST1.1.

• Be 18 years of age or older, ECOG PS: 0-2. Life expectancy of at least 6 months.

• Main organs function is normal.

• The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it.

Exclusion Criteria:

• Patients who had previously received treatment with Antiangiogenic tyrosine kinase inhibitors, such as: Anlotinib, apatinib and Lenvatinib.

• Patients who had previously received local treatment within 4 weeks or Participated in other anti-tumor clinical trials within 4 weeks.

• Patients with previous or current concurrent malignancies or solid organs or bone marrow transplants within 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy

• Unmitigated = grade 2 toxicity (CTC AE 5.0) due to any prior treatment, excluding alopecia.

• With kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus)

• Patients with pleural effusion or ascites.

• Patients with any severe and/or uncontrolled disease.

• Patients who underwent major surgery, open biopsy or significant traumatic injury within 4 weeks.

• Regardless of the severity, patients with any physical signs or history of bleeding, patients with bleeding or bleeding events greater than or equal to CTCAE 2 within four weeks prior to the first administration, or patients with unhealed wounds, fractures, ulcers.

• Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism.

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Neoplasms

Intervention

Drug:
• Anlotinib hydrochloride
Anlotinib hydrochloride may stop the growth of tumor cells and improve iodine uptake.
• Sodium Iodide I 131
RAI treatment may shrink the tumor
• Penpulimab
Penpulimab is a novel structure Immune checkpoint inhibitor. The combination of Penpulimab and RAI might have synergistic effects for DTC.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	objective response rate (ORR)	Proportion of patients with target lesions reaching PR or CR	up to 24 months
Secondary	Disease Control Rate (DCR)	Proportion of patients with target lesions reaching PR, CR or SD	up to 24 months
Secondary	Biochemical Response Rate (BRR)	Biochemical response rate is defined as the percentage of subjects whose Tg was consecutive decreases more than 25% compared to baseline twice	up to 24 months
Secondary	Progression-free Survival (PFS) (median)	PFS was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	up to 24 months
Secondary	Nuclear medicine functional imaging changes of target lesions	The dynamic changes of I uptake and 18F-FDG PET/CT imaging	up to 24 months